Matthew Bick
Matthew Bick is CEO and co-founder at Accipiter Biosciences, a biotechnology startup. He has over 20 years of expertise in leadership and research within therapeutics design, computational protein engineering, and structural biology.
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
Organizations
See all 11-
Accipiter Biosciences CEO and co-founder 2023–present, CSO 2023 · current
-
Accipiter Bio Co-founder and CEO · current
-
Aquinox Pharmaceuticals Senior Director of Protein Sciences 2023, Director of Protein Sciences 2021–2023, Principal Scientist 2020–2021 · past
Education
-
The Rockefeller University PhD, Biophysics · 2003–2010
-
University of Rochester BS, Microbiology · 1995–2000
-
University of North Carolina School of the Arts High School Diploma, Classical Guitar Performance, Composition · 1991–1995
